New Therapeutic Approaches to Large-Vessel Vasculitis
Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are large-vessel vasculitides affecting the aorta and its branches. Arterial damage from these diseases may result in ischemic complications, aneurysms, and dissections. Despite their similarities, the management of GCA and TAK differs. Glucocorticoids are used frequently but relapses are common, and glucocorticoid toxicity contributes to significant morbidity. Conventional immunosuppressive therapies can be beneficial in TAK, though their role in the management of GCA remains unclear. Tumor necrosis factor inhibitors improve remission rates and appear to limit vascular damage in TAK; these agents are not beneficial in GCA. Tocilizumab is the first biologic glucocorticoid-sparing agent approved for use in GCA and also appears to be effective in TAK. A better understanding of the pathogenesis of both conditions and the availability of targeted therapies hold much promise for future management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Annual review of medicine - 75(2024) vom: 29. Jan., Seite 427-442 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaymakci, Mahmut S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologics |
|---|
| Anmerkungen: |
Date Completed 30.01.2024 Date Revised 30.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1146/annurev-med-060622-100940 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361808100 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361808100 | ||
| 003 | DE-627 | ||
| 005 | 20240130232031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1146/annurev-med-060622-100940 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM361808100 | ||
| 035 | |a (NLM)37683286 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaymakci, Mahmut S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New Therapeutic Approaches to Large-Vessel Vasculitis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2024 | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are large-vessel vasculitides affecting the aorta and its branches. Arterial damage from these diseases may result in ischemic complications, aneurysms, and dissections. Despite their similarities, the management of GCA and TAK differs. Glucocorticoids are used frequently but relapses are common, and glucocorticoid toxicity contributes to significant morbidity. Conventional immunosuppressive therapies can be beneficial in TAK, though their role in the management of GCA remains unclear. Tumor necrosis factor inhibitors improve remission rates and appear to limit vascular damage in TAK; these agents are not beneficial in GCA. Tocilizumab is the first biologic glucocorticoid-sparing agent approved for use in GCA and also appears to be effective in TAK. A better understanding of the pathogenesis of both conditions and the availability of targeted therapies hold much promise for future management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Takayasu arteritis | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a giant cell arteritis | |
| 650 | 4 | |a glucocorticoids | |
| 650 | 4 | |a immunosuppressive therapies | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Warrington, Kenneth J |e verfasserin |4 aut | |
| 700 | 1 | |a Kermani, Tanaz A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annual review of medicine |d 1950 |g 75(2024) vom: 29. Jan., Seite 427-442 |w (DE-627)NLM00007831X |x 1545-326X |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2024 |g day:29 |g month:01 |g pages:427-442 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1146/annurev-med-060622-100940 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2024 |b 29 |c 01 |h 427-442 | ||